{"classes":[{"categories":[{"measurements":[{"groupId":"OG005","spread":"0","value":"5"},{"groupId":"OG006","spread":"1","value":"6"},{"groupId":"OG007","spread":"2","value":"7"},{"groupId":"OG008","spread":"2","value":"6"},{"groupId":"OG009","spread":"11","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"8"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG000","title":"CFZ 1.2 mg/m²"},{"description":"Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG001","title":"CFZ 2.4 mg/m²"},{"description":"Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG002","title":"CFZ 4.0 mg/m²"},{"description":"Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG003","title":"CFZ 6.0 mg/m²"},{"description":"Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG004","title":"CFZ 8.4 mg/m²"},{"description":"Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG005","title":"CFZ 11.0 mg/m²"},{"description":"Participants received carfilzomib 15.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG006","title":"CFZ 15.0 mg/m²"},{"description":"Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG007","title":"CFZ 20.0 mg/m²"},{"description":"Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG008","title":"CFZ 27.0 mg/m²"},{"description":"Participants in the Dose Expansion phase received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.","id":"OG009","title":"CFZ 20/27 mg/m² (±DEX)"}],"paramType":"MEAN","populationDescription":"Participants with available pharmacokinetic (PK) data. Tmax was only determined for cohorts receiving carfilzomib ≥ 11 mg/m². For cohorts with carfilzomib dose at 1.2-8.4 mg/m², carfilzomib was measurable at too few time points to allow a good estimation. Participants in the two Dose Expansion cohorts (20/27 mg/m²) were combined for PK analyses.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.","title":"Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)","type":"PRIMARY","unitOfMeasure":"minutes"}